Ascendis Pharma A/S (NASDAQ:ASND – Free Report) had its price target hoisted by Evercore ISI from $191.00 to $205.00 in a report published on Tuesday morning, Benzinga reports. The firm currently has an outperform rating on the biotechnology company’s stock.
A number of other equities analysts have also commented on the stock. Wells Fargo & Company lowered their price target on shares of Ascendis Pharma A/S from $277.00 to $264.00 and set an overweight rating on the stock in a research report on Wednesday, September 4th. Cantor Fitzgerald restated an overweight rating and issued a $170.00 price target on shares of Ascendis Pharma A/S in a research note on Monday, September 16th. The Goldman Sachs Group lifted their target price on shares of Ascendis Pharma A/S from $170.00 to $195.00 and gave the stock a buy rating in a research report on Tuesday, August 13th. JPMorgan Chase & Co. lowered their price target on shares of Ascendis Pharma A/S from $174.00 to $165.00 and set an overweight rating for the company in a report on Wednesday, September 4th. Finally, Bank of America lifted their price objective on shares of Ascendis Pharma A/S from $165.00 to $175.00 and gave the company a buy rating in a research note on Wednesday, September 4th. Two research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of Moderate Buy and an average price target of $193.77.
Get Our Latest Report on Ascendis Pharma A/S
Ascendis Pharma A/S Price Performance
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently bought and sold shares of the company. Avoro Capital Advisors LLC boosted its position in Ascendis Pharma A/S by 5.8% in the second quarter. Avoro Capital Advisors LLC now owns 4,196,661 shares of the biotechnology company’s stock worth $572,341,000 after purchasing an additional 229,995 shares during the last quarter. Westfield Capital Management Co. LP boosted its position in Ascendis Pharma A/S by 1.1% in the first quarter. Westfield Capital Management Co. LP now owns 4,075,214 shares of the biotechnology company’s stock worth $616,050,000 after purchasing an additional 44,580 shares during the last quarter. Capital International Investors boosted its position in Ascendis Pharma A/S by 0.5% in the first quarter. Capital International Investors now owns 2,191,312 shares of the biotechnology company’s stock worth $331,261,000 after purchasing an additional 10,044 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its position in Ascendis Pharma A/S by 23.3% in the first quarter. Price T Rowe Associates Inc. MD now owns 1,781,926 shares of the biotechnology company’s stock worth $269,374,000 after purchasing an additional 336,976 shares during the last quarter. Finally, Massachusetts Financial Services Co. MA boosted its position in Ascendis Pharma A/S by 5.8% in the second quarter. Massachusetts Financial Services Co. MA now owns 1,711,015 shares of the biotechnology company’s stock worth $233,348,000 after purchasing an additional 93,185 shares during the last quarter.
About Ascendis Pharma A/S
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.
Read More
- Five stocks we like better than Ascendis Pharma A/S
- Golden Cross Stocks: Pattern, Examples and Charts
- Analysts Predict 85% Upside for Wave Life Sciences After Rate Cut
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- FedEx Stock Dips: Another Reason to Fear Recession Is Near
- Most Volatile Stocks, What Investors Need to Know
- The Half-Penny Revolution: Will SEC’s Reform Benefit Investors?
Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.